Results 81 to 90 of about 3,722,377 (405)

Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration

BMC Cancer, 2016
Claudin-4 is a transmembrane protein expressed at high levels in the majority of epithelial ovarian tumors, irrespective of subtype, and has been associated with tumor cells that are both chemoresistant and highly mobile.
D. Hicks, Carly E. Galimanis, Patricia G. Webb, M. Spillman, K. Behbakht, M. Neville, H. Baumgartner   +6 more
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

OVARIAN TUMORS

The Professional Medical Journal, 2018
Background: It is mandatory to distinguish between primary ovarian tumorsand metastases, as the treatment and prognoses are wide apart. Immunohistochemistry ismost frequently method being used to distinct these. Multiple studies showed that CDX2 ishallmark of the gut epithelium and is highly sensitive and specific immunohistochemical markerfor ...
Jawad Ali Memon, Zubair Ali
openaire   +3 more sources

Subsequent ovarian yolk sac tumor after operation of ovarian mature teratoma: a case report and review of the literature

Frontiers in Oncology
Ovarian mature teratoma represents a benign ovarian tumor, while ovarian yolk sac tumor (YST, endodermal sinus tumor) is a rare malignant tumor predominantly affecting young women, often associated with a grim prognosis post-metastasis.
Shuqing Li, Juan Peng, Juan Peng, Yajun Zhang, Dongxia Liu, Lei Li, Manman Nai   +6 more
doaj   +1 more source

CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress

BMC Cancer, 2019
Background Recent studies have found that inflammatory response is involved in the pathogenesis of ovarian cancer. Advanced ovarian cancer is often presented with ascites that is rich in cytokines, inflammatory factors or cancer cells.
Jun Shi, Rongfen Huo, Ningli Li, Haichuan Li, Tianhang Zhai, Huidan Li, Baihua Shen, Jing Ye, Ruojin Fu, Wen Di   +9 more
doaj   +1 more source

Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment [PDF]

, 2022
Dan Sun, Xingping Zhao, Yang Yu, Waixing Li, Pan Gu, Zhifu Zhi, Dabao Xu   +6 more
openalex   +1 more source

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Despite initial responsiveness to chemotherapy, the overwhelming majority of advanced ovarian cancer patients relapse with resistant disease. Thus, developing more effective strategies for ovarian cancer treatment is a high clinical priority.
Yanxia Zhao, Jing Cao, A. Melamed, Michael J. Worley, A. Gockley, Dennis Jones, H. Nia, Yanling Zhang, T. Stylianopoulos, A. Kumar, Fotios Mpekris, Meenal Datta, Yao Sun, Limeng Wu, Xing Gao, O. Yeku, M. D. del Carmen, D. Spriggs, R. Jain, Lei Xu   +19 more
semanticscholar   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer

Journal of Translational Medicine, 2009
Background Murine studies suggest that myeloid cells such as vascular leukocytes (VLC) and Tie2+ monocytes play a critical role in tumor angiogenesis and vasculogenesis. Myeloid cells are a primary cause of resistance to anti-VEGF therapy.
Coukos George, Reynolds R Kevin, Kueck Angela S, McLean Karen, Silva Ines A, Spahlinger Gregory, Pulaski Heather L, Conejo-Garcia Jose R, Buckanovich Ronald J   +8 more
doaj   +1 more source

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. [PDF]

, 2019
Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence.
Anderson, Kristen, Barrie, Allison M, Bean, Lisa M, Chen, Xiao Lei, Connolly, Denise C, Cordasco, Edward A, Diaz Osterman, Carlos J, Fisch, Kathleen M, Fu, Guo, Győrffy, Balázs, Heino, Jyrki, Jean, Christine, Jiang, Shulin, Kleinschmidt, Elizabeth G, Kolev, Vihren N, Li, Jian, Mark, Adam M, McHale, Michael T, Molinolo, Alfredo, Ojalill, Marjaana, Ozmadenci, Duygu, Pachter, Jonathan A, Rappu, Pekka, Schlaepfer, David D, Stupack, Dwayne G, Sulzmaier, Florian J, Tancioni, Isabelle, Taylor, Kristin N, Uryu, Sean, Weaver, David T, Xu, Guorong   +30 more
core   +1 more source